What Is Andropause

Andropause refers to the gradual, age-related decline in testosterone and other androgens that occurs in men, typically beginning in the fourth decade of life and progressing steadily thereafter. Unlike the relatively abrupt hormonal shift of menopause, andropause unfolds over decades and varies considerably in pace and severity. The condition is also called late-onset hypogonadism in clinical literature.

Testosterone does far more than regulate libido and sexual function. It influences skeletal muscle maintenance, bone mineral density, red blood cell production, fat distribution, insulin sensitivity, and cognitive function. As levels decline, the downstream effects accumulate across multiple systems, often so gradually that they are attributed to "normal aging" rather than recognized as a hormonal pattern.

From a longevity perspective, the trajectory of testosterone decline intersects with many of the conditions that shorten healthspan. Sarcopenia (muscle loss), visceral fat accumulation, metabolic syndrome, depression, and reduced cardiovascular fitness all correlate with declining androgen levels. Addressing or slowing this hormonal shift does not guarantee protection from these outcomes, but ignoring it removes one of the more actionable levers men have for maintaining function in the second half of life.

Testosterone production depends on a signaling chain called the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary gland to secrete luteinizing hormone (LH). LH then stimulates Leydig cells in the testes to produce testosterone. With aging, this axis becomes less responsive at multiple levels: GnRH pulses become less frequent and robust, the pituitary responds less vigorously, and Leydig cells decline in both number and output.

The decline is compounded by changes in sex hormone binding globulin (SHBG), a protein that binds testosterone in the bloodstream and renders it biologically inactive. SHBG levels tend to rise with age, which means that even if total testosterone appears only modestly reduced, the fraction that is free and available to enter cells may drop more steeply. This distinction between total and free testosterone is clinically important and explains why some men with "normal" total levels still experience significant symptoms.

Other hormones shift in parallel. DHEA (dehydroepiandrosterone), a precursor steroid produced by the adrenal glands, also falls with age. Aromatase, the enzyme that converts testosterone to estradiol, tends to become more active as visceral fat increases, creating a feedback loop: more body fat leads to more estrogen conversion, which suppresses the HPG axis, which lowers testosterone further, which promotes additional fat storage. This aromatase-driven cycle is one reason body composition management is so central to managing andropause.

Andropause does not involve a single hormone. Testosterone is the most prominent marker, but the broader hormonal landscape shifts in several directions simultaneously. DHEA-S, which serves as a precursor for both testosterone and estrogen, declines steadily from its peak in the mid-20s, reaching roughly 10 to 20 percent of peak values by age 70. This decline reduces the raw material available for downstream androgen production.

SHBG, the binding protein that sequesters testosterone in the bloodstream, tends to increase with age. The result is a widening gap between total testosterone (which may look acceptable on a lab report) and free testosterone (the biologically active fraction that actually enters cells). This is why clinicians who specialize in male hormone health test both values rather than relying on total testosterone alone.

Cortisol, the primary stress hormone, has an inverse relationship with testosterone at the receptor level. Chronically elevated cortisol, whether from psychological stress, sleep deprivation, or overtraining, can suppress testosterone synthesis and compete for shared signaling resources. Growth hormone and insulin-like growth factor 1 (IGF-1) also decline with age, compounding the anabolic deficit. Understanding andropause as a multi-hormone shift, rather than a single-hormone deficiency, leads to more effective intervention strategies.

The symptoms of andropause develop gradually, which makes them easy to dismiss. The most commonly reported include reduced libido, erectile changes, persistent fatigue unrelated to exertion, difficulty recovering from exercise, loss of muscle mass despite maintained activity, increased abdominal fat, depressed or flat mood, reduced motivation, and cognitive fog (particularly difficulty with concentration and word retrieval). Sleep disturbances, including insomnia and reduced sleep quality, are also frequently associated with declining androgens.

Not every symptom needs to be present, and severity varies widely between individuals. Some men maintain high function with objectively low testosterone levels, while others become symptomatic at levels still considered within the "normal" laboratory range. This variability is partly genetic, related to androgen receptor sensitivity, and partly influenced by the ratio of free to bound testosterone. Body composition changes are often among the earliest visible signs: a shift from peripheral to central fat distribution, combined with a sense that building or maintaining muscle has become disproportionately difficult, can precede more overt symptoms by years.

Treatment exists on a spectrum from lifestyle modification to pharmaceutical intervention. The foundational layer involves resistance training (which directly stimulates testosterone synthesis), sleep optimization (testosterone is produced primarily during deep sleep), stress management (to reduce cortisol-mediated suppression), and body fat reduction (to limit aromatase conversion). For some men with mild deficits, these measures are sufficient to restore functional hormone levels.

When lifestyle changes are not enough, several clinical options are available. Testosterone replacement therapy (TRT) can be delivered via injections (typically cypionate or enanthate), transdermal gels or creams, or subcutaneous pellets. Each delivery method has trade-offs in terms of dosing consistency, convenience, and side-effect profile. Injections allow precise dosing but produce peaks and troughs in blood levels unless administered frequently. Gels provide more stable levels but carry transfer risk to partners or children.

For men who want to raise testosterone while preserving fertility, alternatives to direct replacement include clomiphene citrate (which stimulates the pituitary to increase LH output) and human chorionic gonadotropin (hCG, which directly stimulates Leydig cells). Some protocols incorporate aromatase inhibitors like anastrozole to manage estrogen conversion, though this approach requires careful monitoring because estradiol plays important roles in bone health and cardiovascular function even in men. Whatever the approach, ongoing blood work is necessary to track not only testosterone and estradiol but also hematocrit, PSA, liver enzymes, and lipid markers.

The existence of age-related testosterone decline is well established through large epidemiological studies, including longitudinal cohorts that have tracked hormone levels in thousands of men over decades. The rate of decline varies across populations, but the general pattern of a one to two percent annual reduction after the mid-30s is consistently observed. Whether this decline constitutes a "disease" or a normal aging process remains debated in endocrinology, and diagnostic thresholds vary between clinical guidelines.

Testosterone replacement therapy has been studied in multiple randomized controlled trials for older men with low levels. These trials generally show improvements in sexual function, mood, and body composition (modest increases in lean mass and decreases in fat mass). The cardiovascular effects remain under active investigation; earlier observational studies raised concerns, but more recent randomized trial data has not confirmed an elevated risk of major cardiovascular events in most populations studied. Effects on prostate tissue are monitored but have not shown the dramatic risk increase once feared. Long-term data spanning more than five to ten years of replacement therapy is still limited, which represents the most significant gap in the evidence base. Lifestyle interventions, particularly resistance training and weight loss, have strong evidence for raising endogenous testosterone in men with suboptimal levels, though the magnitude of the effect varies.

Testosterone replacement therapy suppresses the HPG axis and reduces sperm production, which can impair fertility; men who wish to conceive should discuss alternatives such as selective estrogen receptor modulators or human chorionic gonadotropin with their provider. Exogenous testosterone may increase hematocrit, requiring periodic monitoring of complete blood count to manage polycythemia risk. Prostate-specific antigen (PSA) should be tracked at baseline and during treatment. Self-diagnosis based on symptoms alone is unreliable because fatigue, low mood, and reduced libido have many possible causes. Testosterone obtained outside of medical supervision carries additional risks related to dosing, contamination, and absence of monitoring.